(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The most effective method to Quick Track Your Outcome in Advanced Showcasing with a Web-based Degree - 2November Lease Deals for the 2025 Kia EV6 are Too Good to Pass Up
- 3UPM Adhesive Materials plans new facility near New Delhi, India
- 4NASA astronauts take new moonsuit for a swim | Space photo of the day for Nov. 28, 2025
- 5I traveled to 13 countries in 2025. This small island nation surprised me the most.
- Top 10 Moving Style Architects of the Year
- Porsche May Kill the Electric Boxster Before It Ever Arrives
- Figure out How to Score Huge with Open Record Rewards
- Israel's ban on unsupervised reporters in Gaza causes strategic harm to legitimacy
- From Specialist to Proficient Picture taker: Individual Triumphs
- 7 Odd Apparatuses to Make Your Party Stick Out!
- Space debris: will it take a catastrophe for nations to take the issue seriously?
- 'Tangled' live-action movie casts Teagan Croft and Milo Manheim as Rapunzel and Flynn
- As world leaders enter climate talks, people in poverty have the most at stake
